With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Rs. 40 cr buyback, 200% dividend announced
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Subscribe To Our Newsletter & Stay Updated
